hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia

被引：39

作者：

Bazeos, A. ^{[1
]}

Marin, D. ^{[1
]}

Reid, A. G. ^{[1
]}

Gerrard, G. ^{[1
]}

Milojkovic, D. ^{[1
]}

May, P. C. ^{[1
]}

de Lavallade, H. ^{[1
]}

Garland, P. ^{[1
]}

Rezvani, K. ^{[1
]}

Apperley, J. F. ^{[1
]}

Goldman, J. M. ^{[1
]}

Foroni, L. ^{[1
]}

Khorashad, J. S. ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, London, England

来源：

LEUKEMIA | 2010年 / 24卷 / 06期

关键词：

RESISTANCE; EXPRESSION; CELLS;

D O I：

10.1038/leu.2010.86

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

收藏

页码：1243 / 1245

页数：4

相关论文

共 8 条

[1]

hOCT 1 and resistance to imatinib [J].

Crossman, LC ;

Druker, BJ ;

Deininger, MWN .

BLOOD, 2005, 106 (03) :1133-1134

[2]

INCREASE OF BCR-ABL CHIMERIC MESSENGER-RNA EXPRESSION IN TUMOR-CELLS OF PATIENTS WITH CHRONIC MYELOID-LEUKEMIA PRECEDES DISEASE PROGRESSION [J].

GAIGER, A ;

HENN, T ;

HORTH, E ;

GEISSLER, K ;

MITTERBAUER, G ;

MAIERDOBERSBERGER, T ;

GREINIX, H ;

MANNHALTER, C ;

HAAS, OA ;

LECHNER, K ;

LION, T .

BLOOD, 1995, 86 (06) :2371-2378

[3]

Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia [J].

Kim, Dong Hwan ;

Xu, Wei ;

Ma, Clement ;

Liu, Xiangdong ;

Siminovitch, Katherine ;

Messner, Hans A. ;

Lipton, Jeffrey H. .

BLOOD, 2009, 113 (11) :2517-2525

[4]

MARIN D, J CLIN ONCOL

[5]

Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics [J].

Shu, Y. ;

Brown, C. ;

Castro, R. A. ;

Shi, R. J. ;

Lin, E. T. ;

Owen, R. P. ;

Sheardown, S. A. ;

Yue, L. ;

Burchard, E. G. ;

Brett, C. M. ;

Giacomini, K. M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :273-280

[6]

Active transport of imatinib into and out of cells: implications for drug resistance [J].

Thomas, J ;

Wang, LH ;

Clark, RE ;

Pirmohamed, M .

BLOOD, 2004, 104 (12) :3739-3745

[7]

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia [J].

Wang, L. ;

Giannoudis, A. ;

Lane, S. ;

Williamson, P. ;

Pirmohamed, M. ;

Clark, R. E. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :258-264

[8]

Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance [J].

Zhang, Wenyong W. ;

Cortes, Jorge E. ;

Yao, Hui ;

Zhang, Li ;

Reddy, Neelima G. ;

Jabbour, Elias ;

Kantarjian, Hagop M. ;

Jones, Dan .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) :3642-3649